'I'm delighted': Leadership changes at Newcastle skin health life science firm
SkinBioTherapeutics, a listed Newcastle-headquartered life science group focused on skin health, has appointed a non-executive director and promoted a new chief financial officer.
Alyson Levett has become a non-executive director and chair of the Audit Committee, while Emily Bertram has become chief financial officer and also joined the board. Elsewhere, Danielle Bekker has stepped down from the board but will continue to support as an external advisor effective from 31 December 2025.
Levett has worked in a broad range of sectors including FMCG, food manufacturing, engineering and technology. She has more than 20 years C suite financial experience, culminating in being CFO at the strategy software company, i-nexus where she stayed for a decade taking it onto AIM in a successful IPO in 2018.
Bertram has been promoted from group finance director to chief financial officer and has also become an executive director on the board.
Before SkinBioTherapeutics, she was group head of financial planning and analysis at Azets and has also held positions at THF Holdings, Leica Biosystems, Quantum Pharma, Northumbria University (Faculty of Health & Life Sciences), Alta Link and Northern Rock.
Martin Hunt, chairman of SkinBioTherapeutics, said: "On behalf of the board, I'm delighted to welcome both Alyson and Emily to the board, and congratulate Emily on her promotion. I'd also like to thank Cathy Prescott for the work she's done as Chair of the Audit Committee and for Danielle for staying on as an advisor.
“These appointments strengthen the Board, especially the financial elements and provide welcome support to the Executive Management as we enter a busy 2026."